Joseph Smith Jr. awarded Huggins Medal from the Society of Urologic Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JOSEPH SMITH JR. received the Huggins Medal from The Society of Urologic Oncology, the society’s highest honor, for his lifetime contributions to treatment for patients with genitourinary neoplasms. Smith is a professor of Urologic Surgery at Vanderbilt University Medical Center.

The Huggins Medal is named after Charles B. Huggins, who was awarded the Nobel Prize for Physiology or Medicine in 1966 in recognition of his work on the hormonal treatment of prostate cancer. It is the second major award for Smith from the SUO, having been awarded the SUO Medal in 2006.

Smith received the medal and presented the Huggins lecture at SUO’s 2015 annual winter meeting in Washington, D.C. He was also recently named the next editor of The Journal of Urology.

Smith performed Vanderbilt’s first robotic surgery in 2003 and has completed more than 7,000 prostatectomies since that time. With Smith, VUMC has established itself as a leader in robotic surgery and indications have extended in urology to radical cystectomy, partial nephrectomy and bladder suspension.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login